Rapid diagnosis of Mycobacterium tuberculosis infection in children using interferon-gamma release assays (IGRAs)

Allergy and Asthma Proceedings

Volumn 33, Issue 3, 2012, Pages 217-226

  Riazi, Shahla ^a   Zeligs, Barbara ^a   Yeager, Henry ^a   Peters, Stephen M ^a   Benavides, German A ^a   Di Mita, Onorina ^a   Bellanti, Joseph A ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; GAMMA INTERFERON;

ADOLESCENT; ARTICLE; CHILD; ETHNICITY; FEMALE; GROUPS BY AGE; HUMAN; IN VITRO STUDY; INFANT; INFECTION PREVENTION; INFECTION RISK; INTERFERON GAMMA RELEASE ASSAY; INTERFERON PRODUCTION; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; SCHOOL CHILD; TUBERCULIN TEST; TUBERCULOSIS;

ADOLESCENT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; INTERFERON-GAMMA; INTERFERON-GAMMA RELEASE TESTS; MALE; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 84862509141     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2012.33.3574     Document Type: Article

References (44)

1. Stout JE, and Menzies D. Predicting tuberculosis: does the IGRA tell the tale? Am J Respir Crit Care Med 177:1055-1057, 2008.
2. Starke JR. Interferon-gamma release assays for diagnosis of tuberculosis infection in children. Pediatr Infect Dis J 25:941-942, 2006.
3. Rangaka MX, Wilkinson KA, Glynn JR, et al. Predictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 12:45-55, 2012.
4. Pavić I, Topić RZ, Raos M, et al. Interferon-γ release assay for the diagnosis of latent tuberculosis in children younger than 5 years of age. Pediatr Infect Dis J 30:866-870, 2011.
5. Machingaidze S, Wiysonge CS, Gonzalez-Angulo Y, et al. The utility of an interferon gamma release assay for diagnosis of latent tuberculosis infection and disease in children: a systematic review and meta-analysis. Pediatr Infect Dis J 30:694-700, 2011.
6. Ling DI, Zwerling AA, Steingart KR, et al. Immune-based diagnostics for TB in children: what is the evidence? Paediatr Respir Rev 12:9 -15, 2011.
7. Zhang S, Shao L, Mo L, et al. Evaluation of gamma interferon release assays using Mycobacterium tuberculosis antigens for diagnosis of latent and active tuberculosis in Mycobacterium bovis BCG-vaccinated populations. Clin Vaccine Immunol 17:1985- 1990, 2010.
8. Lalvani A, and Pareek M. Interferon gamma release assays: principles and practice. Enferm Infecc Microbiol Clin 28:245-252, 2010.
9. Connell TG, Ritz N, Paxton GA, et al. A three-way comparison of tuberculin skin testing, QuantiFERON-TB gold and T-SPOT. TB in children. PLoS One 3:e2624, 2008.
10. Dewan PK, Grinsdale J, Liska S, et al. Feasibility, acceptability, and cost of tuberculosis testing by whole-blood interferongamma assay. BMC Infect Dis 6:47, 2006.
11. Cellestis Web page, QuantiFERON-TB Gold In-Tube Test Manufacturer's instructions. Available at: www.cellestis.com; accessed June 11, 2007.
12. Mazurek GH, Jereb J, Lobue P, et al. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep. 2005 Dec 16;54(RR-15):49 -55. Erratum in: MMWR Morb Mortal Wkly Rep. 54(50):1288, December 23, 2005.
13. Mazurek GH, Jereb J, Vernon A, et al. IGRA Expert Committee; Centers for Disease Control and Prevention (CDC). Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection: United States, 2010. MMWR Recomm Rep. 59(RR-5):1-25, 2010.
14. T-SPOT.TB T-Spot.TB is a type of ELISPOT assay, manufactured by Oxford Immunotec Ltd. in the UK, that counts the number of effector T cells that produce gamma interferon stimulated by proteins produced by the bacteria that cause tuberculosis. www.oxfordimmunotec.com.
15. Cruz AT, Geltemeyer AM, Starke JR, et al. Comparing the tuberculin skin test and T-SPOT. TB blood test in children. Pediatrics 127:e31-e8, 2011.
16. Diel R, Loddenkemper R, Meywald-Walter K, et al. Comparative performance of tuberculin skin test, QuantiFERON-TBGold In Tube, and T-Spot. TB test in contact investigations for tuberculosis. Chest 135:1010-1018, 2009.
17. Bua A, Molicotti P, Delogu G, et al. QuantiFERON TB Gold: a new method for latent tuberculosis infection. New Microbiol 30:477-480, 2007.
18. Diel R, Loddenkemper R, Meywald-Walter K, et al. Predictive value of a whole blood IFN-γ assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med 177:1164-1170, 2008.
19. Mori T, Sakatani M, Yamagishi F, et al. Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens. Am J Respir Crit Care Med 170:59-64, 2004.
20. Kang YA, Lee HW, Yoon HI, et al. Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA 293:2756-2761, 2005.
21. Brock I, Munk ME, Kok-Jensen A, et al. Performance of whole blood IFN-γ test for tuberculosis diagnosis based on PPD or the specific antigens ESAT-6 and CFP-10. Int J Tuberc Lung Dis 5:462-467, 2001.
22. Brock I, Weldingh K, Lillebaek T, et al. Comparison of tuberculin skin test and new specific blood test in tuberculosis contacts. Am J Respir Crit Care Med 170:65-69, 2004.
23. Diel R, Ernst M, Döscher G, et al. Avoiding the effect of BCG vaccination in detecting Mycobacterium tuberculosis infection with a blood test. Eur Respir J28:6 -23, 2006.
24. Pareek M, Watson JP, Ormerod LP, et al. Screening of immigrants in the UK for imported latent tuberculosis: a multicentre cohort study and cost-effectiveness analysis. Lancet Infect Dis 11:435-444, 2011.
25. Wang SH, Powell DA, Nagaraja HN, et al. Evaluation of a modified interferon-gamma release assay for the diagnosis of latent tuberculosis infection in adult and paediatric populations that enables delayed processing. Scand J Infect Dis 42:845-850, 2010.
26. Lienhardt C, Fielding K, Hane AA, et al. Evaluation of the prognostic value of IFN-gamma release assay and tuberculin skin test in household contacts of infectious tuberculosis cases in Senegal. PLoS One 5:e10508, 2010.
27. Dyrhol-Riise AM, Gran G, Wentzel-Larsen T, et al. Diagnosis and follow-up of treatment of latent tuberculosis; the utility of the QuantiFERON-TB Gold in-tube assay in outpatients from a tuberculosis low-endemic country. BMC Infect Dis 10:57, 2010.
28. Machado A Jr., Emodi K, Takenami I, et al. Analysis of discordance between the tuberculin skin test and the interferon- gamma release assay. Int J Tuberc Lung Dis 13:446-453, 2009.
29. Nienhaus A, Schablon A, and Diel R. Interferon-gamma release assay for the diagnosis of latent TB infection: analysis of discordant results, when compared to the tuberculin skin test. PLoS One 3:e2665, 2008.
30. Powell RD III, Whitworth WC, Bernardo J, et al. Unusual interferon gamma measurements with QuanitFERON-TB Gold and QuantiFERON-TB In-Tube tests. PLoS ONE 6:1-6, 2011.
31. Centers for Disease Control. Tuberculosis in the United States: 1987. Atlanta, GA: Centers for Disease Control, US Department of Health and Human Services publication (CDC) 89-8322, 1989.
32. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. Am J Respir Crit Care Med 161(4 Pt 1):1376 -1395, 2000.
33. American Academy of Pediatrics, Committee on Infectious Diseases. Update on tuberculosis skin testing of children. Pediatrics 97:282-284, 1996.
34. Starke JR, Jacobs RF, and Jereb J. Resurgence of tuberculosis in children. J Pediatr 120:839-855, 1992.
35. Cantwell MF, Snider DE Jr, Cauthen GM, et al. Epidemiology of tuberculosis in the United States, 1985 through 1992. JAMA 272:535-539, 1994.
36. American Academy of Pediatrics, Committee on Infectious Diseases. Tuberculosis. In Report of the Committee on Infectious Diseases, 1991. 22nd ed. Elk Grove Village, IL: American Academy of Pediatrics, 492-493, 1991.
37. American Academy of Pediatrics. Tuberculosis. In Red book: 2009 report of the Committee on Infectious Disease, 28th ed. Pickering LK, Baker CJ, Kimberlin DW, and Long SS, (Eds). Elk Grove Village, IL: American Academy of Pediatrics, 680 - 701, 2009.
38. NICE Guidelines. CG33 Tuberculosis: Full Guideline. 22 March 2006.
39. Taylor RE, Cant AJ, and Clark JE. Potential effect of NICE tuberculosis guidelines on paediatric tuberculosis screening. Arch Dis Child 93:200-203, 2008.
40. Holland SM, Freeman AF, and Bellanti JA. Immunity to bacteria. In Immunology IV. Clinical applications in health and disease. Bellanti JA (Ed). Bethesda: I Care Press, 429-457, 2012.
41. Krummel B, Strassburg A, Ernst M, et al. Potential role for IL-2 ELISpot in differentiating recent and remote infection in tuberculosis contact tracing. PLoS One 5:e11670, 2010.
42. Lighter J, Rigaud M, Huie M, et al. Chemokine IP-10: an adjunct marker for latent tuberculosis infection in children. Int J Tuberc Lung Dis 1:731-736, 2009.
43. Ruhwald M, Petersen J, Kofoed K, et al. Improving T-cell assays for the diagnosis of latent TB infection: potential of a diagnostic test based on IP-10. PLoS One 3:e2858, 2008.
44. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology. America College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic diseasemodifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 59:762-784, 2008.